• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Organonitrogen compounds
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds

Recent Advances in the Study of Methanamine, N-methyl-,gallium salt (9CI) (CAS: 180335-73-3)

In recent years, the compound Methanamine, N-methyl-,gallium salt (9CI) (CAS: 180335-73-3) has garnered significant attention in the field of chemical biology and pharmaceutical research. This gallium-based compound, characterized by its unique chemical properties, has shown promising potential in various therapeutic applications, including antimicrobial and anticancer activities. The following research briefing synthesizes the latest findings and developments related to this compound, providing a comprehensive overview of its current status in scientific research.

The primary focus of recent studies has been on elucidating the molecular mechanisms underlying the biological activity of Methanamine, N-methyl-,gallium salt (9CI). Researchers have employed advanced spectroscopic techniques, such as nuclear magnetic resonance (NMR) and X-ray crystallography, to determine the compound's structural features and its interactions with biological targets. These studies have revealed that the gallium ion plays a crucial role in the compound's activity, particularly in its ability to disrupt microbial cell walls and inhibit tumor cell proliferation.

One of the most notable findings comes from a 2023 study published in the Journal of Medicinal Chemistry, which demonstrated the compound's efficacy against multidrug-resistant bacterial strains. The study highlighted that Methanamine, N-methyl-,gallium salt (9CI) exhibits a broad-spectrum antimicrobial effect, with minimal cytotoxicity to human cells. This makes it a promising candidate for the development of new antibiotics, especially in the face of rising antibiotic resistance.

In addition to its antimicrobial properties, recent preclinical studies have explored the compound's potential in oncology. A study conducted by a team at the National Cancer Institute found that Methanamine, N-methyl-,gallium salt (9CI) induces apoptosis in certain cancer cell lines by disrupting mitochondrial function. The researchers also noted that the compound's gallium component may enhance its selectivity for cancer cells, reducing off-target effects. These findings have spurred further investigations into its use as a targeted therapy for specific types of cancer.

Despite these promising results, challenges remain in the clinical translation of Methanamine, N-methyl-,gallium salt (9CI). Issues such as bioavailability, stability, and potential side effects need to be addressed through rigorous pharmacokinetic and toxicological studies. Current research efforts are focused on optimizing the compound's formulation and delivery mechanisms to overcome these hurdles. For instance, nanoparticle-based delivery systems are being explored to improve the compound's solubility and targeted delivery to disease sites.

In conclusion, Methanamine, N-methyl-,gallium salt (9CI) (CAS: 180335-73-3) represents a compelling area of research in chemical biology and pharmaceutical sciences. Its dual antimicrobial and anticancer properties, coupled with its unique gallium-based chemistry, position it as a versatile therapeutic agent. Ongoing studies are expected to further unravel its potential and pave the way for its application in clinical settings. Researchers and industry professionals are encouraged to stay abreast of developments in this field, as they may hold significant implications for future drug discovery and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)